Drug Profile

Tetrapeptide analgesic - PVP Labs

Alternative Names: L-tyrosyl-D-arginyl-L-phenylalanylglycinamide; Taphalgin; TAPHALGIN^®

Latest Information Update: 20 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PVP Labs
Class Non-opioid analgesics; Peptides
Mechanism of Action Calcium channel modulators; OPRM1 protein agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Marketed Postoperative pain
Phase III Cancer pain

Most Recent Events

20 Mar 2026 Launched for Postoperative pain in Russia (SC), prior to March 2026
17 Mar 2026 Chemical structure information added.
10 Mar 2026 Efficacy data from a phase III trial in Postoperative pain released by PVP Labs (PVP Labs website, March 2026)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com